TY - JOUR
AB - 96 British Hair and Nail Society BH02 (P25) British Hair and Nail Society Assessing the clinicophenotypic characteristics and metabolic changes in males with early-onset Orals androgenetic alopecia and altered hormonal profile: a comparative cross-sectional study BH01 Vinay Keshavamurthy, Rajsmita Bhattacharjee, Methotrexate monotherapy for alopecia universalis: a Anuradha Bishnoi, Akanksh Kaushik, Naresh successful treatment not to be overlooked Sachdeva, Arnab Pal, Tarun Narang and Sunil Dogra Sophie Rolls PGIMER, Chandigarh, India St Woolos’ and The Royal Gwent Hospital, Newport, UK Men with early-onset androgenetic alopecia (AGA) are at a Alopecia areata (AA) has a lifetime risk of 2% and carries huge significantly increased risk of insulin resistance, obesity, dia- psychological burden. Management of this refractory disease is betes mellitus and cardiovascular disease, and frequently show challenging. There is no standard treatment that is consistently an abnormal hormonal milieu (Cannarella R, Condorelli RA, effective and therefore therapeutic options are numerous. Dall’Oglio F et al. Increased DHEAS and decreased total testos- Methotrexate (MTX) is a conventional therapy for autoim- terone serum levels in a subset of men with early-onset andro- mune and inflammatory conditions, and is well tolerated. genetic alopecia: does a male PCOS-equivalent exist? Int J Despite lack of high-quality randomized 
TI - BH01: Methotrexate monotherapy for alopecia universalis: a successful treatment not to be overlooked
JO - British Journal of Dermatology
DO - 10.1111/bjd.21329
DA - 2022-07-01
UR - https://www.deepdyve.com/lp/oxford-university-press/bh01-methotrexate-monotherapy-for-alopecia-universalis-a-successful-zsx2cIv52f
SP - 96
EP - 96
VL - 187
IS - S1
DP - DeepDyve
ER -